Viewing Study NCT07054567


Ignite Creation Date: 2025-12-25 @ 12:46 AM
Ignite Modification Date: 2025-12-25 @ 10:59 PM
Study NCT ID: NCT07054567
Status: RECRUITING
Last Update Posted: 2025-11-17
First Post: 2025-06-20
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer
Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module